21 March 2023
Watch Anteris CEO, Wayne Paterson, present at the NWR Virtual Healthcare Conference.
WATCH MORE RECENT INTERVIEWS
16 Feburary 2023
Anteris CEO, Wayne Paterson, talks $35 million raise and 2023 milestones with Proactive Investors;
06 December 2022
Anteris CEO Wayne Paterson highlights recent news that the USA FDA has conditionally approved the DurAVR™ transcatheter heart valve (THV) system.
28 November 2022
A panel discussion on the formal results of a comparative study which investigated aortic flow physiology by cardiac MRI (cMRI) in five patients who received a DurAVR™ transcatheter aortic valve (first-in-human). The study compared DurAVR™ to normal age-height-weight matched controls, other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR).
Anteris presents detailed results of the 30-day outcomes for the combined cohort of 13 patients, from the DurAVR™ THV First-In-Human (FIH) trial at the world’s premier meeting for interventional cardiovascular medicine.
Anteris Technologies DurAVR™ Transcatheter Heart Valve showcased on Channel 9, Australia, at our Malaga, Perth facility.
MORE RECENT PRESENTATIONS
Anteris Technologies 2023 Annual General Meeting
Download Here
DurAVR™ Transcatheter Aortic Valve First-in-Human Study: Impact of Novel Leaflet Design
Presentation Deck: PCR London Valves
Anteris Technologies 2022 Annual General Meeting
Anteris Technologies CEO, Wayne Paterson is Live in the Cath Lab.
LATEST ANTERIS ARTICLES
29 May 2023
We are pleased to provide the attached Chairman’s Address and Chief Executive Officer Presentation to the Annual General Meeting.
View Presentation
24 May 2023
"A new-look transcatheter aortic valve replacement (TAVR) device designed to mimic the patient’s native aortic valve is associated with strong safety outcomes and a “promising hemodynamic performance” after one year, according to new data published in EuroIntervention.[1]"
22 May 2023
First in Human Results Presented at EuroPCR with Simultaneous Publication in EuroIntervention
Key Highlights:
- The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study demonstrated promising haemodynamic performance sustained to 1 year and restoration of nearnormal blood flow dynamics.
- DurAVR™ THV demonstrated an outstanding safety profile: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction were reported during any follow-up visits.
- These encouraging preliminary First-in-Human study results will be futher validated in an FDA-approved Early Feasibility Study (EFS) commencing soon.
Proactive Investors: Anteris Technologies unveils encouraging FIH results from DurAVR™ heart valve study - 22 May 2023
17 May 2023
Anteris Technologies Granted Additional Utility Patent
Anteris is pleased to announce that the United States Patent and Trademark Office has issued another utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
Stockhead: Anteris issued another utility patent in US - 17 May 2023
19 April 2023
Agreement to Develop New Heart Valve Repair Device
Anteris is pleased to announce that the Company has entered an agreement with v2vmedtech, inc. to partner with leading physicians to develop an innovative heart valve repair device for the minimally invasive treatment of mitral and tricuspid valve regurgitation (“Devices”) – also known as a leaky valve – a market expected to be $4.1 Billion by 2028.
Read More:
AFR: Anteris Technologies strikes US cardiology deal - 19 April 2023
Stockhead: Anteris to develop innovative heart valve repair device - 19 April 2023
12 April 2023
Anteris Technologies awarded utility patent
The US Patent and Trademark Office has issued a utility patent for the novel transcatheter heart valve replacement technology.
21 Mar 2023
Presentation at NWR Virtual Healthcare Conference
Anteris CEO Wayne Paterson, presents at the NWR Virtual Healthcare Conference on Tuesday 21 March 2023.
15 Feb 2023
Settlement of $35M Capital Raising Transaction
A successful settlement of 1.458 million new ordinary shares in the Company to various sophisticated and professional investors at an issue price of $24.00 per New Share, raising $35 million cash.
09 Feb 2023
FDA Grants Expanded Approval for the DurAVR™ EFS
The United States Food and Drug Administration (FDA) has granted expanded approval for the DurAVR™ THV System in Subjects with Severe Aortic Stenosis: Early Feasibility Study (EFS).
Proactive Investors: Anteris receives FDA expanded approval for DurAVR™ EFS - 9 Feb 2023
06 Feb 2023
Proposed $50 Million Capital Facility
Anteris is pleased to announce that the Company has entered into a non-binding agreement with Yorkville Advisors Global, LP (Investor) to provide a $50 million SEPA facility to Anteris.
16 Jan 2023
DurAVR™ First in Human Study 12 Month Results
Key Highlights
- The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study met all performance endpoints with remarkable hemodynamic function sustainedto 12 months.
- DurAVR™THV demonstrated an outstanding safety profile. All safety endpoints were met: No mortality(all causes), no disabling stroke,nolife-threatening bleeding, and no myocardial infarction at 12 months.
- These encouraging preliminary First-in-Human study results will be further validated in an FDA-approvedEarly Feasibility Study (EFS) in early 2023.
Proactive Investors: Anteris delivers strong 12-month results from DurAVR™ FIH study - 16 Jan 2023
06 Dec 2022
Anteris hails FDA early feasibility study approval for DurAVR™
CEO Wayne Paterson discusses with Proactive the news that the USA FDA has conditionally approved the DurAVR™ (THV) system for investigational device exemption (IDE) application to kick off an early feasibility study (EFS). The study will evaluate the safety and feasibility of the DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.
28 Nov 2022
FDA approves Early Feasibility Study for the DurAVR™ THV System
Anteris is pleased to announce the U.S. Food and Drug Administration (FDA) has conditionally approved the DurAVR™ Transcatheter Heart Valve (THV) System for investigational device exemption (IDE) application to commence an Early Feasibility Study (EFS).
09 Nov 2022
Anteris Technologies receives exciting acknowledgment as a "Top 10 MedTech Startup 2022" by industry publication MedTech Outlook.
09 Nov 2022
CEO Magazine - Spotting Opportunities
When CEO and Managing Director Wayne Paterson joined Anteris Technologies he took the opportunity to shift the focus from competing in a A$50 Million sector to entering a A$15 Billion Industry
28 Sep 2022
Anteris has valve world talking about 'human-like characteristics' of DurAVR™
Anteris' CEO Wayne Paterson speaks with Proactive about its productive presentation at the annual TCT medical conference, the world’s largest interventional cardiology conference. 30-Day clinical data was presented for its full cohort of 13 patients implanted with DurAVR™ THV during its First-In-Human trial. It compared the results with outcomes of its most recent 22 patient study, which showed DurAVR™ THV technology performed favourably against other transcatheter aortic valve replacements and surgical aortic valve replacements at six months.
19 Sep 2022
Results Demonstrating Restoration of Normal Pre-Disease Flow
Anteris presents preliminary results demonstrating for the first-time restoration of normal pre-disease blood flow after aortic valve replacement at (TCT) conference, the world's foremost meeting of interventional cardiologists. In a study of 22 patients comparing valve flow amongst current aortic valve replacement technologies, Anteris demonstrated no significant difference to the normal healthy aortic valve’s flow with DurAVR™ THV. When current generation TAVR (transcatheter aortic valve replacement) and SAVR (surgical aortic valve replacement) valves were compared to the healthy aortic valve,both groups demonstrated statistically significant worse flow.
11 Jul 2022
Update on First In Human DurAVR™ THV Study
Anteris reports the 30-day follow-up results on the second cohort of (eight) patients showed clinically significant improvements.
21 Jun 2022
DurAVR™ First In Human Patient 6 Month Study Follow Up
Anteris is pleased to announce the 6 month follow up of our first cohort of 5 patients. The 6 month follow up is informal (formal follow ups according to the study protocol are 30 days and 1 year). All patients are doing very well and in fact have shown marked improvements since the 3 month follow up.
06 Jun 2022
Local Australian News, Channel 9, interview and cover Anteris at our Malaga Facility.
06 Jun 2022
06 Jun 2022
Anteris CEO Wayne Paterson interviews the implanting physicians from the DurAVR™ First-in-Human Study
2 Mar 2022
Investment of 20 Million into Anteris
We are pleased to announce Perceptive Life Sciences has invested USD 20 million into Anteris
25 Jan 2022
Anteris Technologies' 30-day data
30-day data released from in-human heart valve trial yields promising results
24 Jan 2022
Anteris Reports Successful Interim Results for the First-in-Human Trial for DurAVR
25 Nov 2021
The Science behind a Valve Designed for Life - Dr Christopher Meduri
An Expert Interview with Dr C. Meduri from Karolinska University Hospital (Stockholm – SE) where he discusses the “The Science Behind a Valve Designed for Life” at PCR London Valves 2021
25 Nov 2021
Anteris' CEO talks 'outstanding results'
Anteris Technologies CEO talks 'outstanding results' from first human DurAVR patients with Proactive Investors